# A Clinical Study to Evaluate the Safety and Efficacy of ESO-T01 in Treating Relapsed/Refractory Multiple Myeloma.

> **NCT06691685** · EARLY_PHASE1 · RECRUITING · sponsor: **Union Hospital, Tongji Medical College, Huazhong University of Science and Technology** · enrollment: 24 (estimated)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** ESO-T01 Injection

## Key facts

- **NCT ID:** NCT06691685
- **Lead sponsor:** Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-11-18
- **Primary completion:** 2027-11-01
- **Final completion:** 2027-11-01
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2025-03-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06691685

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06691685, "A Clinical Study to Evaluate the Safety and Efficacy of ESO-T01 in Treating Relapsed/Refractory Multiple Myeloma.". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT06691685. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*